刘国恩获中国药学发展奖特别贡献奖 推动药物经济学开创性研究与政策实践

Core Insights - The article emphasizes the importance of drug economics in evaluating not only drug prices but also the cost savings associated with medications, including their impact on hospitalization duration, patient experience, and reduction of side effects and complications [2]. Group 1: Drug Economics - Liu Guoen, the director of the Peking University Global Health Development Institute, calls for the advancement of drug economics in China, highlighting its urgency and significance [2]. - Drug economics should consider the comparative effectiveness and costs of prescription drugs against other medications, as well as their broader implications on healthcare costs [2]. Group 2: Awards and Recognition - The 19th China Pharmaceutical Development Award recognized five individuals with the "Special Contribution Award," including Liu Guoen for his pioneering research and policy contributions in drug economics [2][3]. - Liu Guoen has made significant contributions to the field, including serving as a deputy editor for major international journals and founding China's first official journal on drug economics [4]. Group 3: Policy and Research Contributions - Since 2011, Liu Guoen has been a member of the State Council's Medical Reform Expert Advisory Committee, contributing to national healthcare policy [5]. - Liu Guoen leads a team that is developing the "Planetary Health Axis System," an AI-based system aimed at tracking and assessing health metrics across various dimensions [6]. Group 4: Challenges in Drug Evaluation - Liu Guoen points out the need for improved quality in generic drugs and the challenges faced by innovative drugs due to insufficient real-world data during early market entry [6]. - He stresses the necessity for continuous innovation in drug economic evaluation methods and the active participation of researchers in policy discussions to promote sustainable healthcare development [6].